Aladote presented as a novel emerging treatment of paracetamol overdose at two scientific conferences.

Stockholm, Sweden, February 10, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that its drug candidate Aladote® will be presented at two upcoming scientific conferences in March and April.

Aladote is presented by Professor James Dear from the University of Edinburgh, UK, at the annual meeting of the Society of Toxicology (SOT) on March 16, at 11.00am ET/7.00pm CET under the heading Novel Emerging Treatments for Acetaminophen Toxicity; and at the annual scientific meeting of the American College of Medical Toxicology (ACMT) on April 14, at 5.00pm ET/11.00pm CET under the heading Antidote Updates.

Professor Dear is an internationally leading expert in the treatment of paracetamol poisoning and was the principal investigator of the Aladote phase Ib/IIa study conducted at the Royal Infirmary of Edinburgh and The Queen's Medical Research Institute, the University of Edinburgh.

Both presentations are pre-recorded talks in symposiums, followed by live Q&A sessions. No abstracts are published.

About Egetis Therapeutics

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate® is a first in class drug candidate developed for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial was completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated in Dec 2020 with the first patient dosed and interim results are expected in 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that Pledox did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx® will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com